Targeting BTK in CLL: Beyond Ibrutinib.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 3, p. 197, doi. 10.1007/s11899-019-00512-0
- By:
- Publication type:
- Article
Works matching IS 15588211 AND DT 2019 AND VI 14 AND IP 3
Results: 8
1
2
Integrative Approaches to Managing Myeloproliferative Neoplasms: the Role of Nutrition, Exercise, and Psychological Interventions.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 3, p. 164, doi. 10.1007/s11899-019-00516-w
- By:
- Publication type:
- Article
3
Next-Generation Sequencing in Myeloproliferative Neoplasms: Is This Indicated in All Patients?
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 3, p. 137, doi. 10.1007/s11899-019-00514-y
- By:
- Publication type:
- Article
4
Trends in Clinical Benefits and Costs of Novel Therapeutics in AML: at What Price Does Progress Come?
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 3, p. 171, doi. 10.1007/s11899-019-00510-2
- By:
- Publication type:
- Article
5
Disparities in Survival and Health Outcomes in Childhood Leukemia.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 3, p. 179, doi. 10.1007/s11899-019-00515-x
- By:
- Publication type:
- Article
6
Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 3, p. 154, doi. 10.1007/s11899-019-00509-9
- By:
- Publication type:
- Article
7
Expert Panel Consensus Statement for Proper Evaluation of First Relapse in Multiple Myeloma.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 3, p. 187, doi. 10.1007/s11899-019-00507-x
- By:
- Publication type:
- Article
8
Key Role of Inflammation in Myeloproliferative Neoplasms: Instigator of Disease Initiation, Progression. and Symptoms.
- Published in:
- Current Hematologic Malignancy Reports, 2019, v. 14, n. 3, p. 145, doi. 10.1007/s11899-019-00508-w
- By:
- Publication type:
- Article